ARYx Therapeutics Files For IPO
Fremont-based ARYx Therapeutics has filed for an IPO, saying in a filing with the SEC Thursday afternoon that the firm is looking to IPO on the NASDAQ Global Market as "ARYX." The firm is looking to raise up to $86.25M in the IPO, which is being underwritten by Morgan Stanley, CIBC World Markets, Jeffries & Company, and Leerink Swann & Company. ARYx, which develops biopharmaceuticals, has a compound which just completed Phase II trials focused on treatment of gastroesophageal reflux disease (GERD). The company is venture backed by MPM Capital, Nomura Phase4 Ventures, OrbiMed Advisors, and others.
posted on Thursday, August 30, 2007
Related companies:
ARYx Therapeutics
Related stories:
> Sofinnova Ventures Names EIR
> Bayhill Therapeutics Files For IPO
> Merck Buys Sirna Therapeutics
> Iconic Therapeutics Finds $20M
> Hyperion Therapeutics Files For IPO
silicontap.com Home